Skip to content
Screener

Cytek Biosciences, Inc. CTKB Cash Flow Statement

Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
-$6.1M-11.3%-$12.16M-118%-$18.87M-65.5%-$44.08M—-$5.48M-682%
$2.11M+10.2%$2.01M+6.3%$1.87M-0.5%$1.9M+2.3%$1.92M+3.6%
$4.85M-13.9%$5.34M-21.4%$4.86M-26.7%$5.53M-21.1%$5.64M-20.1%
-$4.45M-14.2%——-$2.74M-2,089%-$771K-139%-$3.9M-129%
$1.51M+129%$2.22M+40.5%$2.17M+155%$1M+12.0%$657K-35.0%
-$1.8M-110%——-$27.08M-386%——$18.92M+220%
$0—$0-100%$0-100%————
$1.06M-49.3%$41K-97.0%$5.07M+634%$1.42M-49.2%$2.09M+41,720%
$2.37M+1,531%$1.61M+1,036%$869K-42.8%$2.94M+2,015%$145K+3.6%
————$3.98M+134%-$1.23M+66.3%——
-$6.66M———-$25.19M-631%-$2.43M+96.2%——
-$5.96M-30.8%-$849K+42.2%-$4.9M-403%-$1.77M-261%-$4.56M-137%

FAQ

What is Cytek Biosciences, Inc.'s free cash flow?
After $6.9M of capital expenditures, Cytek Biosciences, Inc.'s free cash flow was -$13.5M over the trailing twelve months, down 128.7% year over year.
Where does Cytek Biosciences, Inc.'s cash flow data come from?
Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.